DXA-measured body composition effects of GLP-1 and dual GIP/GLP-1 receptor agonists in adults with obesity or type 2 diabetes: analysis code and data (version 2.0, revised for BMC Endocrine Disorders)

Read full text Summarise with VIRAT
Authors: Birkan ALAYCI, Öykü Zeynep Gerçek
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Data and R code for the systematic review and meta-analysis of phase 3 randomized trials reporting DXA-derived lean body mass and fat mass with GLP-1 and dual GIP/GLP-1 receptor agonists (PROSPERO CRD420261323497), published as: Alaycı B, Gerçek ÖZ. DXA-measured lean and fat mass differences with incretin-based therapy versus comparators: a meta-analysis of phase 3 trials. BMC Endocrine Disorders. 2026. https://doi.org/10.1186/s12902-026-02679-z (Article in Press, 21 October 2026). The article refers to release v2.1. Version 2.1.2 (October 2026) updates the documentation and metadata only (README.md, CHANGELOG.md, CITATION.cff and this metadata file); no data, code or output changed from version 2.1.1. Version 2.1.1 added the audit addendum on the SUSTAIN-8 sample sizes to version 2.1. No extracted value changed from version 2.0. The principal presentation is stratified by population and comparator type, the five-trial pooled estimate is a secondary summary, and the meta-regression, small-study tests and pooled lean proportion were withdrawn at version 2.1. New at 2.1: the RoB 2 assessment against the specific estimand synthesized (rob2/), searches of trial registries and sponsor repositories for unpublished DXA outcomes (searches/), and the independent human audit of data extraction (audit/). The analysis (glp1_dxa_meta_v1_3.R, revision_analyses.R, refresh_forests_v1_3.R) implements the REML + Hartung-Knapp-Sidik-Jonkman primary model, prediction intervals, tau-squared estimator comparison, profile-likelihood intervals, robust variance estimation, a three-level model, leave-one-out and expanded-inclusion analyses, and Bayesian random-effects models (brms, bayesmeta) with prior sensitivity. All outputs (tables, figures, console log) are included; see README.md and CHANGELOG.md.

Fields of Study & Subjects

Diabetes Treatment and Management Pharmacology and Obesity Treatment Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
22 March 2026
Language
EN